進階篩選

Technical category
    • Application of inorganic nanofiber technology to promote the development of biotechnology

      Smart machinerynovel materials FutureTech Application of inorganic nanofiber technology to promote the development of biotechnology

      Inorganic porous nanofibers with surfaceinterface defects are prepared through humidity-controlled electrospinninghigh-temperature annealing technology. Under the irradiation of light sources of different wavelengths (380~780 nm), the bound electrons stored in the valence band can be excited to the conduction band to form free electrons on the surface of the material, generating different intensities of microcurrents, light sensitivitymicrocurrent changes. Because the "inorganic nanofiber" technology has high uniquenesshigh product compatibility, it can be applied to a wide range of markets.
    • (test)Application of inorganic nanofiber technology to promote the development of biotechnology

      Smart machinerynovel materials FutureTech (test)Application of inorganic nanofiber technology to promote the development of biotechnology

      Inorganic porous nanofibers with surfaceinterface defects are prepared through humidity-controlled electrospinninghigh-temperature annealing technology. Under the irradiation of light sources of different wavelengths (380~780 nm), the bound electrons stored in the valence band can be excited to the conduction band to form free electrons on the surface of the material, generating different intensities of microcurrents, light sensitivitymicrocurrent changes. Because the "inorganic nanofiber" technology has high uniquenesshigh product compatibility, it can be applied to a wide range of markets.
    • 百發百中、相醫維命 – 發展伴隨式診斷以進行小分子RNA干擾片段的癌症精準醫療

      Precision Health Ecosystem FutureTech 百發百中、相醫維命 – 發展伴隨式診斷以進行小分子RNA干擾片段的癌症精準醫療

      Cancer is the first leading cause of death in Taiwan. Targeted therapy allows the cancer cells to be specifically targeted, reduces the side effects,achieves the purpose of precision cancer treatment. This report contains two invention technologies which combined early & specific diagnosis of a specific Aurora-A mRNA isoform in cancers (the companion diagnosis)the treated with a selective locked nucleic acid (LNA)-modified novel double-stranded short interfering nucleic acid (siRNA) to inhibit the translation of this Aurora-A mRNA isoform (targeted therapy) in cancers.